Vaccines against chlamydial infection

A technology for chlamydia and chlamydia protein, which is applied in the field of vaccines against chlamydia infection, and can solve problems such as infection effects

Inactive Publication Date: 2013-10-30
GLAXOSMITHKLINE BIOLOGICALS SA +1
View PDF74 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because the genomic makeup of C. trachomatis is relatively stable and because the presence of animal hosts is negligible, even vaccines with limited efficacy may have a significant impact on the prevalence of infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccines against chlamydial infection
  • Vaccines against chlamydial infection
  • Vaccines against chlamydial infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0489] Example 1: Expression and purification of Chlamydia trachomatis recombinant protein

[0490] Several C. trachomatis genes were cloned into plasmids incorporating a 6X histidine tag at the N-terminus to allow expression and purification of recombinant proteins.

[0491] Two full-length recombinant proteins, Ct-622 and Ct-875, were expressed in E. coli. CtL2 and CtE expression screens were used to identify these two genes and express serotype E homologues. Primers used to amplify these genes were based on serotype L2 / E sequences. Genes were amplified using serotype E genomic DNA as a template. Once amplified, the fragment was cloned into pET-17b with an N-terminal 6X-His tag. After transformation of the recombinant plasmids into XL-I blue cells, DNA was prepared and the clones were fully sequenced. The DNA was then transformed into the expression host BL21-pLysS (Novagen) for recombinant protein production. Proteins were induced with IPTG and purified on Ni-NTA agaro...

Embodiment 2

[0497] Example 2: Formulation of five different Chlamydia trachomatis antigen combinations and adjuvants

[0498] The antigen combinations in the table below were prepared as follows. 5 μg of each antigen was mixed in 50 μl PBS and then mixed with 50 μl AS01B adjuvant comprising 3D-MPL and QS21 formulated with cholesterol-containing liposomes to a total volume of 100 μl per dose.

[0499] After mixing with the antigen, the final composition of the adjuvant is:

[0500]

[0501]

Embodiment 3

[0502] Example 3: Testing of Combinations of Chlamydia Trachomatis Antigens in a Mouse Model - Immunization Against Chlamydia Genital Tract Infection

[0503] This example demonstrates that vaccination with the combination of Chlamydia antigens described in Example 2 can significantly protect mice from Chlamydia infection.

[0504] A murine model of genital tract infection by human Chlamydia trachomatis (Ct) serotype K strains was developed that closely resembles the mechanism of infection in humans. This model was used to evaluate the effectiveness of immunizing mice with various combinations of Ct-specific antigens from different serotypes. Specifically, Balb / c mice and C57Bl / 6 mice were inoculated with the formulations of the adjuvant combinations described in Example 2. This model was also tried with a third mouse strain, DBA, but this model was not immune to Ct challenge, which did not occur in the positive control (UV-irradiated Chlamydia elegans (UVEB) formulated in AS...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.

Description

[0001] This application is a divisional application with application number 200680019142.6, claiming priority on March 31, 2005. field of invention [0002] The present invention generally relates to the treatment or prevention of Chlamydia infection. In particular, the present invention relates to polypeptides comprising chlamydia antigens and compositions of combinations thereof, and to polynucleotides encoding chlamydia antigens and compositions of combinations thereof, and to the use of these compositions in the prophylactic or therapeutic treatment of chlamydia infection the use of. Background of the invention [0003] Chlamydia are intracellular bacterial pathogens that cause a variety of important human and animal infections. [0004] Chlamydia trachomatis is transmitted between humans through social or sexual contact. Multiple serotypes of C. trachomatis exist, and although identification and classification of serotypes continues, at least 18 have been reported to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/118A61P31/04
CPCA61K2039/55572A61K2039/55577C07K14/295A61K39/118A61P31/00A61P31/04A61P33/02A61K39/395A61K38/16
Inventor B.巴斯A.巴蒂亚M.阿尔德森J.-F.L.迈松纳夫Y.洛贝尔F.B.诺扎伊M.马尚P.梅滕斯Y.A.斯凯基P.普罗布斯特
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap